Trials / Withdrawn
WithdrawnNCT00785694
Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, comparative, multicentre study to determine if the early recurrence rate of intermediate-risk bladder cancer is similar in subjects treated with multiple instillations of mitomycin C after resection conducted under white light cystoscopy (group A) and subjects treated with 1 instillation of mitomycin C after resection conducted under white light and blue light cystoscopy (group B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hexaminolevulinate | Instillation of 50mL of 8mM Hexvix into the bladder through a catheter. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2008-11-05
- Last updated
- 2015-04-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00785694. Inclusion in this directory is not an endorsement.